The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting

키워드

참고문헌 (32)

1. Gaspersz R, "The role of anxious distress in immune dysregulation in patients with major depressive disorder", Transl Psychiatry, 7, pp.1268~ (2017)
2. Zimmerman M, "Reliability and validity of the DSM-5 anxious distress specifier interview", Compr Psychiatry, 76, pp.11~17 (2017)
3. Uher R, "Major depressive disorder in DSM-5 : implications for clinical practice and research of changes from DSM-IV", Depress Anxiety, 31, pp.459~471 (2014)
4. Liu ST, "The clinical observation of inflammation theory for depression : the initiative of the formosa long COVID multicenter study(FOCuS)", Clin Psychopharmacol Neurosci, 21, pp.10~18 (2023)
5. Shin C, "Efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression : a randomized rater-blinded 6-week clinical trial", Clin Psychopharmacol Neurosci, 21, pp.135~146 (2023)
6. Pae CU, "Aripiprazole in the treatment of depressive and anxiety disorders : a review of current evidence", CNS Drugs, 22, pp.367~388 (2008)
7. Han C, "Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?", CNS Drugs, 27(Suppl 1), pp.S47~S51 (2013)
8. Han C, "The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier : a retrospective study", Clin Psychopharmacol Neurosci, 17, pp.495~502 (2019)
9. Wang Y, "A preliminary study of different treatment strategies for anxious depression", Neuropsychiatr Dis Treat, 18, pp.11~18 (2022)
10. Woo YS, "Korean medication algorithm project for bipolar disorder 2022, fifth revision : an executive summary", Clin Psychopharmacol Neurosci, 20, pp.747~761 (2022)
11. Wang SM, "Second generation antipsychotics in the treatment of major depressive disorder : an update", Chonnam Med J, 52, pp.159~172 (2016)
12. Han C, "The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder", J Psychiatr Res, 56, pp.72~81 (2014)
13. Pae CU, "Clinical issues in use of atypical antipsychotics for depressed patients", CNS Drugs, 27(Suppl 1), pp.S39~S45 (2013)
14. Pae CU, "Aripiprazole as adjunctive therapy for patients with major depressive disorder : overview and implications of clinical trial data", CNS Drugs, 25, pp.109~127 (2011)
15. Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
16. Hamilton M, "Development of a rating scale for primary depressive illness", Br J Soc Clin Psychol, 6, pp.278~296 (1967)
17. Guy W, "ECDEU assessment manual for psychopharmacology-revised, 1976", National Institute of Mental Health, US Department of Health, Education, and Welfare, ~ (1976)
18. Schaffer A, "The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders", Ann Clin Psychiatry, 24, pp.6~22 (2012)
19. Kamijima K, "Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder", Curr Med Res Opin, 34, pp.2105~2112 (2018)
20. Huang CW, "Trends and factors in antipsychotic use of outpatients with anxiety disorders in Taiwan, 2005-2013 : a population-based study", Psychiatry Clin Neurosci, 73, pp.501~507 (2019)
21. McIntyre RS, "Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants : a case review study", Adv Ther, 32, pp.429~444 (2015)
22. Ozaki N, "Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder : a subgroup analysis and Montgomery-Åsberg depression rating scale and hamilton rating scale for depression item analyses of the aripiprazole depression multicenter efficacy study", Psychiatry Clin Neurosci, 69, pp.34~42 (2015)
23. Trivedi MH, "Adjunctive aripiprazole in major depressive disorder : analysis of efficacy and safety in patients with anxious and atypical features", J Clin Psychiatry, 69, pp.1928~1936 (2008)
24. Katzman MA, "Aripiprazole : a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness", J Affect Disord, 128(Suppl 1), pp.S11~S20 (2011)
25. Worthington JJ 3rd, "Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients", Int Clin Psychopharmacol, 20, pp.9~11 (2005)
26. Mallinckrodt CH, "Differential antidepressant symptom efficacy : Placebo-controlled comparisons of duloxetine and SSRIs(fluoxetine, paroxetine, escitalopram)", Neuropsychobiology, 56, pp.73~85 (2007)
27. Hieronymus F, "Influence of baseline severity on the effects of SSRIs in depression : An item-based, patient-level post-hoc analysis", Lancet Psychiatry, 6, pp.745~752 (2019)
28. Shin C, "Additional reduction of residual symptoms with aripiprazole augmentation in the patients with partially remitted major depressive disorder", Clin Psychopharmacol Neurosci, 19, pp.243~253 (2021)
29. Hiranyatheb T, "The impact of residual symptoms on relapse and quality of life among Thai depressive patients", Neuropsychiatr Dis Treat, 12, pp.3175~3181 (2016)
30. Kim HJ, "Efficacy of aripiprazole as adjunctive therapy in major depressive disorder with somatic symptoms : a randomized, double-blind, placebo-controlled trial with clinical and electroencephalography evidence", J Psychopharmacol, 37, pp.289~302 (2023)
31. Rush AJ, "STAR*D : what have we learned?", Am J Psychiatry, 164, pp.201~204 (2007)
32. Kamijima K, "Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder : a randomized, double-blind, placebo-controlled study(ADMIRE study)", J Affect Disord, 151, pp.899~905 (2013)

관련 논문AI추천